Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: gemcitabine, cytarabine, gemcitabine hydrochloride +4 | 1.00 |
| trials ClinicalTrials.gov | 17 Parkinson's trials, 3 stopped | 0.86 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 17 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11189
Sealed predictions
- POLD4 in dopamine neurons, braak-0.23 (p 0.551) → -0.61 (p 0.084)receipt 11195
Swarm cases
receipt 11195: POLD4 in dopamine neurons, braak
- power
- full sample -0.36 (p 0.142, n 18), 95% CI -0.71 to +0.13. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.095, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.067, n 18). could be the mix.
- skeptic
- leave-one-out range -0.51 to -0.28, sign flips 0; without severely affected donors -0.36 (p 0.142, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for POLD4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts